| abstract |
The present disclosure provides anti-TGFbetaRII immunoglobulin single variable domains. Suitably, the anti-TGFbetaRII immunoglobulin single variable domains according to the present disclosure may comprise SEQ ID NOs: 1-38, 204, 206, 208, 214, 234, 236, 238, 240, 263, 265, 267, 269, Having an amino acid sequence as set forth in any one of 271, 273, 275, 277, 279, 281, 283, 285, 287, 289 or 291 and having up to 5 amino acid substitutions, deletions or additions. The present disclosure relates to diseases associated with TGFbeta signaling and suitably lung fibrosis, including tissue fibrosis such as idiopathic pulmonary fibrosis; Liver fibrosis, including cirrhosis and chronic hepatitis; Rheumatoid arthritis; Eye disorders; Fibrosis of the skin, including keloids of the skin; Duputen building; Kidney fibrosis such as nephritis and neurosis; Wound healing; Reduced scarring; And polypeptides and pharmaceutical compositions for the treatment of vascular conditions, such as diseases selected from the group of restenosis. |